

DHRUVI PHARMA PRIVATE LIMITED

ANNUAL REPORT

2021-22

DHRUVI PHARMA PVT. LTD.**BALANCE SHEET AS AT 31ST MARCH, 2022**

Particulars	Note No.	(Rs. In lakhs)	
		As At 31st March 2022	As At 31st March 2021
I. EQUITY AND LIABILITIES			
(1) Shareholder's Funds			
(a) Share Capital	2	768.00	921.00
(b) Reserves and Surplus	3	1,508.42	1,185.68
(2) Non-Current Liabilities			
(a) Long Term Borrowings	4	878.50	340.50
(b) Long Term Provisions	5	38.18	34.42
(3) Current Liabilities			
(a) Short Term Borrowings	6	3,371.22	2,861.07
(b) Trade Payables	7		
To Micro and Small Enterprise			
To Others		NIL	NIL
(c) Other Current Liabilities	8	1,387.50	1,983.28
(d) Short-Term Provisions	9	107.81	105.67
		125.30	112.57
Total Equity & Liabilities		8,184.94	7,544.19
II. ASSETS			
(1) Non-Current Assets			
(a) Property, Plant & Equipment and Intangible Assets	10		
(i) Property, Plant & Equipment		122.67	116.04
(ii) Intangible Assets		0.10	0.10
(iii) Total Net Block		122.77	116.13
(b) Non Current Investments	11	1,265.80	766.00
(c) Deferred Tax Asset	12	101.76	77.57
(d) Other Non Current Assets	13	26.21	27.68
(2) Current Assets			
(a) Inventories	14	2,596.95	2,578.26
(b) Trade Receivables	15	3,561.35	3,678.02
(c) Cash and Cash Equivalents	16	21.62	48.90
(d) Short Term Loans and Advances	17	488.48	251.62
Total Assets		8,184.94	7,544.19
Significant Accounting Policies	1		
Notes on Financial Statement	2 to 29		

Notes referred to above and notes attached there to form an integral part of Balance Sheet
This is the Balance Sheet referred to in our Report of even date.

For Hemanshu Shah & Co.
Chartered Accountants
Firm Registration No. 122439W

H.C. Shah
Partner
Membership No. 36441

Place : Ahmedabad
Date : 2nd June, 2022



For and on behalf of the Board

Rupesh Hemendra Shah
Managing Director
DIN: 00029134

Arvind Kumar Venkat
Director
DIN: 02304618




DHRUVI PHARMA PVT. LTD.**STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31ST MARCH, 2022**

(Rs. In lakhs)

Sr. No	Particulars	Note No.	For The Year Ended 31 March 2022	For The Year Ended 31 March 2021
I	Revenue From Operations	18	38,579.99	35,048.55
II	Other Income	19	34.88	3.56
III	Total Revenue		38,614.88	35,052.11
	Expenses:			
	Purchase of Stock-in-Trade	20	35,972.69	32,415.92
	Changes in inventories of Stock-in-Trade	21	(18.69)	306.75
	Employment Benefit Expenses	22	908.65	808.85
	Financial Costs	23	303.07	272.13
	Depreciation and Amortization Expenses	24	129.29	81.57
	Other Expenses	25	679.60	550.61
IV	Total Expenses		37,974.60	34,435.83
V	Profit before tax (III -IV)		640.27	616.28
VI	Tax expense:			
	(1) Current tax		185.72	172.69
	(2) Deferred tax		(24.18)	6.44
	(3) Provision for taxation for Earlier Year		-	(21.62)
VII	Profit For The Year (V-VI)		478.74	458.77
VIII	Earning per equity share:	26		
	(1) Basic		30.69	29.41
	(2) Diluted		30.69	29.41
	Significant Accounting Policies	1		
	Notes on Financial Statement	2 to 29		

Notes referred to above and notes attached there to form an integral part of Profit & Loss Statement
This is the Profit & Loss Statement referred to in our Report of even date.


For Hemanshu Shah & Co.
Chartered Accountants
Firm Registration No. 122439W


H.C. Shah
Partner
Membership No. 36441




Place : Ahmedabad
Date : 2nd June, 2022

For and on behalf of the Board


Rupesh Hemendra Shah
Managing Director
DIN: 00029134




Arvind Kumar Venkat
Director
DIN: 02304618

DHRUVI PHARMA PVT. LTD.**STATEMENT OF CASHFLOWS FOR THE YEAR ENDED 31ST MARCH, 2022**

PARTICULARS	(Rs. In lakhs)	
	31.03.2022	31.03.2021
A. Cash Flow from operating activities		
Net Profit / Loss before Tax	640.27	616.28
Adjustments for		
Depreciation and Amortisation	129.29	81.57
Interest & Finance Charges	303.07	272.13
Interest Income	(34.88)	(3.56)
Bad debts	4.15	1.50
Operating Profit before Working Capital Changes	1,041.89	967.92
Adjustments for		
Decrease/(Increase) in Trade and other receivable	112.52	161.51
Decrease/(Increase) in Inventories	(18.69)	306.75
Increase/(Decrease) in Trade Payables	(595.78)	(803.20)
Decrease/(Increase) Other Liabilities and Provisions	(228.66)	104.01
Cash generated from Operations	311.28	736.99
Taxes Paid	(175.28)	(171.92)
Net Cash Flow from Operating Activities (A)	136.00	565.07
B. Cash Flow from Investing Activities		
Purchase of Fixed Assets	(135.93)	(130.90)
Decrease/(Increase) in Loans and advances	1.47	(5.72)
Investments in equity shares of subsidiary company	(499.80)	(10.00)
Interest Income	34.88	3.56
Net Cash (used in)/ from investing activities (B)	(599.37)	(134.06)
C. Cash Flow from Financing Activities		
Redemption of Preference Shares	(153.00)	NIL
Proceeds from Long Term Borrowings	538.00	40.50
Repayment of Short Term Borrowings	NIL	(182.74)
Proceeds from Short Term Borrowings	510.15	NIL
Repayment of Long Term Borrowings	NIL	NIL
Dividend Paid	(156.00)	NIL
Interest & Finance charges paid	(303.07)	(272.13)
Net Cash (used in) / from financing activities (C)	436.09	(414.36)
Net increase in Cash & Cash Equivalents (A+B+C)	(27.28)	16.65
Opening Balance of Cash & Equivalents	48.90	32.25
Closing Balance of Cash & Equivalents	21.62	48.90

This is the Cash Flow Statement referred to in our Report of even date.

For Hemanshu Shah & Co.
Chartered Accountants
Firm Registration No. 122439W

H.C. Shah
Partner
Membership No. 36441

Place : Ahmedabad
Date : 2nd June, 2022



For and on behalf of the Board

Rupesh Hemendra Shah
Managing Director
DIN: 00029134

Arvind Kumar Venkat
Director
DIN: 02304618



DHRUVI PHARMA PRIVATE LIMITED

NOTES TO ACCOUNTS FOR THE YEAR ENDED 31st MARCH 2022

Significant Accounting Policies, Standards and Notes on Accounts

1. Significant Accounting Policies and Standards:

a) Basis of Preparation

These financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India ('Indian GAAP') to comply with the Accounting Standards specified under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and the relevant provisions of the Companies Act, 2013. The financial statements have been prepared under the historical cost convention on accrual basis.

b) Use of estimates

The preparation of financial statements requires the management of the company to make estimates and assumptions that affect the reported balances of assets and liabilities and disclosures relating to the contingent liabilities as at the date of the financial statements and reported amounts of income and expense during the year. Examples of such estimates include provisions for doubtful receivables, employee benefits, provision for income taxes and accounting for contract costs expected to be incurred, the useful lives of depreciable fixed assets and provisions for impairment. Future results could differ due to changes in these estimates and the difference between the actual result and the estimates are recognized in the period in which the results are known / materialize.

c) Inventories

The inventories of all medicines, Medicare items traded and dealt with by the company are valued at cost. Cost of these inventories comprise of all costs of purchase and other costs incurred in bringing the inventories to their present location after adjusting for GST wherever applicable, applying the FIFO method.

d) Revenue Recognition

Income from Sale of goods (i.e. Life Saving Medicines and Medicare items) has been recognized on billing of such goods. Accounting policies unless referred to otherwise, are in accordance with the generally accepted accounting principles.

Interest income on term deposits with Banks is recognized on time proportion basis taking into account the amount outstanding and the rate applicable.



DHRUVI PHARMA PRIVATE LIMITED

NOTES TO ACCOUNTS FOR THE YEAR ENDED 31st MARCH 2022

Significant Accounting Policies, Standards and Notes on Accounts

e) Fixed assets

Fixed Assets are shown at cost of acquisition less accumulated depreciation thereon. Cost of acquisition comprising of the purchase price and any attributable cost of bringing the asset to working condition for the intended use. Subsequent expenditure related to an item of fixed asset is added to its book value only if it increases the future benefits from the exiting asset beyond its previously assessed standard of performance. All other Expenses on existing fixed assets, including day-to-day repair and maintenance expenditure and cost of replacing parts, are charged to the statement of profit and loss for the period during which such expenses are incurred.

f) Impairment

At each balance sheet date, the management reviews the carrying amounts of its tangible assets included in each cash generating unit to determine whether there is any indication that those assets were impaired. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of impairment.

If the recoverable amount of an asset is estimated to be less than its carrying amount the carrying amount of the asset is reduced to its recoverable amount. Impairment losses are recognized as an expense to the extent that they exceed any revaluation surplus already recognized in respect of those assets.

Where impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount but not exceeding the carrying amount that would have been determined had no impairment loss has been recognized for the asset in prior years when the cost model is used for that asset. A reversal of the impairment loss is recognized as income immediately to the extent that a revaluation deficit or impairment loss was recognized as expense previously. The excess is treated as revaluation surplus if a fair value model is used in respect of that asset.

g) Depreciation

In respect of fixed assets (other than freehold land and capital work-in-progress) acquired during the year, depreciation / amortization is charged on WDV basis so as to write off the cost of the asset over the useful lives and for the assets acquired prior to April 1, 2014, the carrying amount as on April 1, 2014 is depreciated over the remaining useful life based on an evaluation.



DHRUVI PHARMA PRIVATE LIMITED

NOTES TO ACCOUNTS FOR THE YEAR ENDED 31st MARCH 2022

Significant Accounting Policies, Standards and Notes on Accounts

The company follows the written down value method of charging depreciation on its fixed assets based on their useful lives given in schedule II of companies act, 2013 except for software which have been amortized over a period 3 years.

<u>Type of asset</u>	<u>Period (Useful life)</u>
Computer & Data processing units	
i) Servers & Networks	3 years
ii) End user devices such as desktops, laptops, etc.	3 years
Motor Vehicles	
i) Motor cars other than those used in a business of running them on hire	8 years
Office equipment	5 years
Electrical Installations & equipment	10 years
Furniture and Fixtures	10 years

h) Investments

Long-term investments and current maturities of long-term investments are stated at cost, less provision for other than temporary diminution in value.

i) Benefits to Employees

- i. **Provident Fund:** The company contributes to the employee's provident fund (a defined contribution benefit) maintained under the Employees Provident fund Scheme by the central government.
- ii. **Gratuity:** Gratuity are recognized as an expense in the profit and loss account for the year in which the employee has rendered services. The expenses are recognized at the present value of the amount payable determined using actuarial valuation techniques. Actuarial gain in respect of gratuity benefits is charged to the profit and loss account.

DHRUVI PHARMA PRIVATE LIMITED

NOTES TO ACCOUNTS FOR THE YEAR ENDED 31st MARCH 2022

Significant Accounting Policies, Standards and Notes on Accounts

j) Taxes on Income

Tax on income for the current period is determined on the basis of taxable income and tax credits computed in accordance with the provisions of the Income Tax Act, 1961 and based on the expected outcome of assessments/appeals.

Deferred tax expense or benefit is recognized on timing differences being the difference between taxable incomes and accounting income that originate in one period and is likely to reverse in one or more subsequent periods. Deferred tax assets and liabilities are measured using the tax rates and tax laws that have been enacted or substantively enacted as on the balance sheet date.

In the event of unabsorbed depreciation and carry forward of losses, deferred tax assets are recognized only to the extent that there is virtual certainty supported by convincing evidence that sufficient future taxable income will be available to realise such assets. In other situations, deferred tax assets are recognized only to the extent that there is reasonable certainty that sufficient future taxable income will be available to realise these assets.

The Company offsets deferred tax assets and deferred tax liabilities if it has a legally enforceable right and these relate to taxes on income levied by the same governing taxation laws.

k) Earnings per share

The company reports basic and diluted earnings per share in accordance with Accounting Standard 20 "Earning per Share". Basic earnings per share are computed by dividing the net profit attributable to equity shareholders for the year by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the net profit or loss for the period by the weighted average number of equity shares outstanding during the period as adjusted for the effects of all the dilutive potential equity shares, except where the results are anti-dilutive.

l) Cash and cash equivalents

The Company considers all highly liquid financial instruments, which are readily convertible into known amounts of cash that are subject to an insignificant risk of change in value and having original maturities of three months or less from the date of purchase, to be cash equivalents.



DHRUVI PHARMA PRIVATE LIMITED

NOTES TO ACCOUNTS FOR THE YEAR ENDED 31st MARCH 2022

Significant Accounting Policies, Standards and Notes on Accounts

m) Provisions, Contingent liabilities and Contingent assets

A provision is recognized when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

All known liabilities whenever material are provided for and liabilities which are material and whose future outcome cannot be ascertained with reasonable certainty are treated as contingent and disclosed by way of Notes to the Accounts.



Sr. No	Particulars	As At 31st March 2022	As At 31st March 2021
2. SHARE CAPITAL			
1 AUTHORIZED CAPITAL			
	19,00,000 Equity Shares of Rs. 10/- each	190.00	190.00
	1,00,000 6% Redeemable Non-cumulative Non Convertible Preference Shares of Rs.10 each	10.00	10.00
	76,50,000 0% Redeemable Non-convertible Preference Shares of Rs.10 each	765.00	765.00
	Total	<u>965.00</u>	<u>965.00</u>
2 ISSUED , SUBSCRIBED & PAID UP CAPITAL			
	15,60,000 Equity Shares of Rs. 10/- each	156.00	156.00
	61,20,000 0% Redeemable Non-convertible Preference Shares of Rs.10 each(FY 2020-21-76,50,000 Shares)	612.00	765.00
	Total	<u>768.00</u>	<u>921.00</u>
3 RECONCILIATION OF NUMBER OF SHARES OUTSTANDING			
		Equity Shares	
		Numbers	Amount
		Equity Shares	
		Numbers	Amount
	Shares Outstanding as on 1st April 2021	15.60	15.60
	Shares Outstanding as on 31st March 2022	15.60	15.60
		Preference Shares	
		Numbers	Amount
		Preference Shares	
		Numbers	Amount
	Shares Outstanding as on 1st April 2021	76.50	76.50
	Redemption	15.30	-
	Shares Outstanding as on 31st March 2022	61.20	76.50
4 Class & Par Value of Shares			
	Company has only one class of Equity Shares of Par Value of Rs.10/-		
	Company has only one class of preference Shares of Par Value of Rs.10/-		
5 Rights, Preferences & Restrictions of the Class of Share Holders			
	The Company has one class of equity shares. Each equity share entitles the holder to one vote. The final dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts in proportion to their shareholding.		
	The Company has one class of Preference shares. The holder of preference shares is entitled to vote for the resolutions which directly affects the rights attached to their shares. Preference share holders are not entitled to participate in surplus fund. In the event of liquidation, the preference shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts but before equity share holders.		

DHRUVI PHARMA PVT. LTD.**Notes Forming Integral Part of the Balance Sheet as at 31st March, 2022****6 DETAILS OF EQUITY SHAREHOLDERS/PROMOTER**

Name of the Shareholder	As At31st March 2022		As At31st March 2021	
	No. of Shares	%	No. of Shares	%
Keimed Pvt. Ltd.	10.92	70	10.92	70
Rupesh H. Shah	2.34	15	2.34	15
Deepti R. Shah	2.34	15	2.34	15

7 DETAILS OF PREFERENCE SHAREHOLDERS

Name of the Shareholder	As At31st March 2022		As At31st March 2021	
	No. of Shares	%	No. of Shares	%
Keimed Pvt. Ltd.	42.84	70.00	53.55	70.00
Rupesh H. Shah	3.18	5.20	3.98	5.20
Deepti R. Shah	3.18	5.20	3.98	5.20
Pushpa Suresh Ajmera	6.00	9.80	7.50	9.80
Suresh Chabildas Ajmera	6.00	9.80	7.50	9.80

8 Company is a subsidiary company of Keimed Pvt. Ltd.

9 Shares allotted as fully paid up without payment being received in cash during the period of five years immediately preceding 31.03.2022 being the date of Balance sheet

13,00,000 new equity shares of Rs. 5/- each allotted as bonus shares during FY 2015-16.

DHRUVI PHARMA PVT. LTD.

Notes Forming Integral Part of the Balance Sheet as at 31st March, 2022

6 DETAILS OF EQUITY SHAREHOLDERS/PROMOTER

Name of the Shareholder	As At 31st March 2022		As At 31st March 2021	
	No. of Shares	%	No. of Shares	%
Keimed Pvt. Ltd.	10.92	70	10.92	70
Rupesh H. Shah	2.34	15	2.34	15
Deepthi R. Shah	2.34	15	2.34	15

7 DETAILS OF PREFERENCE SHAREHOLDERS

Name of the Shareholder	As At 31st March 2022		As At 31st March 2021	
	No. of Shares	%	No. of Shares	%
Keimed Pvt. Ltd.	42.84	70.00	53.55	70.00
Rupesh H. Shah	3.18	5.20	3.98	5.20
Deepthi R. Shah	3.18	5.20	3.98	5.20
Pushpa Suresh Ajmera	6.00	9.80	7.50	9.80
Suresh Chabildas Ajmera	6.00	9.80	7.50	9.80

8 Company is a subsidiary company of Keimed Pvt. Ltd.

9 **Shares allotted as fully paid up without payment being received in cash during the period of five years immediately preceeding 31.03.2022 being the date of Balance sheet**

13,00,000 new equity shares of Rs. 5/- each allotted as bonus shares during FY 2015-16.

DHRUVI PHARMA PVT. LTD.

Notes Forming Integral Part of the Balance Sheet as at 31st March, 2022

Particulars	(Rs. In lakhs)	
	As At 31st March 2022	As At 31st March 2021
3. RESERVES AND SURPLUS		
Surplus (Profit & Loss Account):-		
Balance brought forward from previous year	1,185.68	726.91
Add: Profit for the year	478.74	458.77
Less: Appropriation		
Final Dividend	156.00	NIL
Transfer to Capital Redemption Reserve	153.00	NIL
Total	1,355.42	1,185.68
Capital Redemption Reserve Account		
Balance brought forward from previous year	NIL	NIL
Add: Transfer from Profit & Loss Account	153.00	NIL
Total	1,508.42	1,185.68
4. LONG TERM BORROWINGS		
Loans from related parties		
Unsecured		
- From Directors	478.50	340.50
- From Keimed Pvt. Ltd.	400.00	NIL
Total	878.50	340.50
Note : Efferctive Rate of Interest is 8.5%.		
5. LONG TERM PROVISIONS		
-Provision for employee benefits (Refer Note No. 29 (d))	38.18	34.42
Total	38.18	34.42
6. SHORT TERM BORROWINGS		
Loan Repayable on Demand		
Secured		
- Woking capital loan from bank	3,371.22	2,861.07
Total	3,371.22	2,861.07

Note:- Working capital by bank is secured by first charge on the company's Stocks & Book Debts. Keimed Pvt Ltd has given corporate gurantee and Directors, Mr Rupesh Shah and Mrs Deepti Shah have provided personal gurantee to banks for working capital loan.

DHRUVI PHARMA PVT. LTD.

Notes Forming Integral Part of the Balance Sheet as at 31st March, 2022

Particulars	As At 31st March 2022	As At 31st March 2021
7. TRADE PAYABLES		
Total outstanding due of micro enterprises and small enterprises	NIL	NIL
Total outstanding dues of creditors other than micro enterprises and small enterprises	1,387.50	1,983.28
Total outstanding due of micro enterprises and small enterprises-Disputed	NIL	NIL
Total outstanding dues of creditors other than micro enterprises and small enterprises - Disputed	NIL	NIL
Total	1,387.50	1,983.28
Trade Payable Aging		
Total outstanding dues of creditors other than micro enterprises and small enterprises		
Outstanding for Less Than 1 Year	1,387.50	1,983.28
Outstanding for 1 - 2 Years	-	-
Outstanding for 2 - 3 Years	-	-
Outstanding for More Than 3 Years	-	-
Total	1,387.50	1,983.28
Note :		
Details of Dues to Micro, Small & Medium Enterprises as defined under MSMED Act, 2006 This information, as required to be disclosed under the Micro, Small and Medium Enterprises Development Act 2006, has been determined to the extent such parties have been identified on the basis of information available with the Company. This has been relied upon by the auditors.		
8. OTHER CURRENT LIABILITIES		
TDS/TCS payable	19.31	10.58
GST payable	79.67	89.08
Other Statutory dues payable	5.57	5.17
Other payable	3.26	0.84
Total	107.81	105.67
9. SHORT TERM PROVISIONS		
Provision For Employees Benefit		
Bonus	27.11	27.97
Gratuity (refer note no 29(d))	1.65	2.46
Leave Encashment	28.68	25.79
Provisions		
Provision for Income Tax	11.21	0.77
Provision for Expenses	56.65	55.58
Total	125.30	112.57

DHRUVI PHARMA PVT. LTD.

Notes Forming Integral Part of the Balance Sheet as at 31st March, 2022

Particulars	(Rs. In lakhs)	
	As At 31st March 2022	As At 31st March 2021
11. NON CURRENT INVESTMENT		
Investments in Unquoted Equity Instruments		
Investments in subsidiary at cost		
5,10,000 equity shares of face value of Rs. 10 each of ATC Pharma Pvt Ltd - (P.Y. 5,10,000)	765.00	765.00
10,000 equity shares of face value of Rs. 10 each of Yashvi Pharma Pvt. Ltd. at Face Value	1.00	1.00
51,000 equity shares of face value of Rs. 100 each of Anila Medical Pvt. Ltd.(P.Y. - NIL)	499.80	NIL
Total	1,265.80	766.00
12. DEFERRED TAX ASSET		
In respect of Property, Plant & Equipment	84.91	69.38
In respect of various disallowance under Income Tax Act	16.85	8.19
Total	101.76	77.57
13. OTHER NON CURRENT ASSETS		
i) Security Deposits		
Rent Deposits	25.31	26.73
Security Deposits	0.90	0.96
Total	26.21	27.68
14. INVENTORIES		
Stock in trade	2,596.95	2,578.26
Total	2,596.95	2,578.26
Note : 1) Stock is valued at cost and NRV which ever is less		
2) The above inventory is hypothecated to bank		
15. TRADE RECEIVABLES		
Undisputed:		
Undisputed Trade Receivables considered good	3,561.35	3,678.02
Undisputed Trade Receivables considered doubtful	NIL	NIL
Disputed:		
Disputed Trade Receivables considered good	NIL	NIL
Disputed Trade Receivables considered doubtful	NIL	NIL
Total	3,561.35	3,678.02
Trade Receivables ageing		
1) Undisputed Trade Receivables considered good		
Less Than 6 Months	3,475.65	3,580.21
6 Months-1 Year	77.02	63.68
1-2 years	6.27	32.97
2-3 Years	2.41	1.15
More than 3 Years	-	-
Total	3,561.35	3,678.02

DHRUVI PHARMA PVT. LTD.

Notes Forming Integral Part of the Balance Sheet as at 31st March, 2022

Particulars	(Rs. In lakhs)	
	As At 31st March 2022	As At 31st March 2021
16. CASH & CASH EQUIVALENTS		
<u>Cash-in-Hand</u>		
Cash Balance	10.95	27.08
Sub Total	10.95	27.08
<u>Bank Balance</u>		
- Balance with Nationalised/Schedule Banks	5.13	16.29
- Other bank balance		
In Deposit Accounts with Nationalised / Schedule Banks	5.53	5.53
Sub Total	10.66	21.82
Total	21.62	48.90
17. SHORT TERM LOANS AND ADVANCES		
<u>Loans to Related Parties</u>		
Unsecured loan to subsidiary company (refer note no 28 and 29(y))	421.00	140.00
<u>Other</u>		
Advance tax	-	-
Advances to employees	24.96	10.42
Advance to suppliers	-	25.82
Deposits	12.76	10.77
Balances with Statutory authorities	7.60	7.60
Prepaid Expenses	10.22	6.16
Refund- Income Tax	11.94	50.85
Total	488.48	251.62

DHRUVI PHARMA PVT. LTD.

Notes Forming Integral Part of the Balance Sheet as at 31st March, 2022

(Rs. In lakhs)

Particulars	As At 31st March 2022	As At 31st March 2021
18. Revenue from Operations		
Sale of products	38,579.87	35,047.21
Other operating revenues	0.12	1.34
Total	38,579.99	35,048.55
19. Other Income		
Interest income	34.88	25.18
Total	34.88	25.18
20. Purchase of Stock-in-Trade		
Purchase of stock in trade	35,972.69	32,415.92
Total	35,972.69	32,415.92
21. Change in Inventories		
Opening Stock of Stock in trade	2,578.26	2,885.01
Less: Closing Stock of Stock in trade	2,596.95	2,578.26
Total	(18.69)	306.75
22. Employment Benefit Expenses		
Salaries and wages	674.79	590.56
Directors Remuneration	72.00	72.00
Contribution to provident fund	38.02	36.31
Contribution to ESI	19.54	17.36
Bonus expense	49.91	47.53
Gratuity	5.83	5.31
Leave Encashment	28.92	26.07
Insurance Premium Employees	0.29	3.20
Staff Welfare Expenses	19.36	10.52
Total	908.65	808.85
23. Financial Costs		
Interest expense -Working Capital loan	230.96	223.39
Interest expense on unsecured loan	62.56	30.34
Bank Charges	9.55	5.40
Interest on delay payment of Statutory dues	NIL	13.00
Total	303.07	272.13

DHRUVI PHARMA PVT. LTD.
Notes Forming Integral Part of the Balance Sheet as at 31st March, 2022

(Rs. In lakhs)

Particulars	As At 31st March 2022	As At 31st March 2021
24. Depreciation & Amortised Cost		
Depreciation on Property, plant and Equipements	129.29	81.57
Amortisation of Intangible assets	NIL	NIL
Total	129.29	81.57
25. Other Expenses		
Establishment Cost		
Rent Expenses	134.81	110.06
Repairs & Maintenance Expenses	7.22	2.53
House Keeping Expenses	14.40	11.12
Electricity Charges	33.07	26.99
Sub Total	189.50	150.70
Operating Cost		
Vehicle Repairs & Maintenance	7.41	6.94
Equipments -Repairs & Maintenance Exepenses	27.08	18.44
Petrol / Diesel Expenses	49.97	42.74
Software Expenses	15.54	1.68
Freight Inward Expenses	9.03	9.63
Annual Maintenance Charges	11.39	6.90
Conveyance Expenses	1.24	8.79
Travelling Expenses	6.28	4.82
Insurance Expenses	9.79	7.05
Sub Total	137.73	106.99
Administration Expenses		
Printing & Stationery Expenses	16.36	12.90
Telephone Charges	4.02	4.30
Rates & Taxes	2.37	0.95
Statutory Audit Fees Expenses	7.80	6.65
Internal audit Fees Expenses	3.40	3.16
Legal & Professional Charges	8.94	8.80
Misc. Expenses	9.02	2.93
Security Charges	8.95	9.10
CSR Expenses	10.85	8.48
Sub Total	71.71	57.27

DHRUVI PHARMA PVT. LTD.

Notes Forming Integral Part of the Balance Sheet as at 31st March, 2022

(Rs. In lakhs)

Particulars	As At 31st March 2022	As At 31st March 2021
Selling & Distribution Cost		
Business Promotion Expense	6.31	2.21
Sales Commission Expense	10.16	9.50
Freight Outwards & Coolie	33.58	23.78
Packing Charges	33.41	23.43
Logistic Charges	193.05	175.23
Bad Debts	4.15	1.50
Sub Total	280.66	235.65
Total	679.60	550.61

26. Earnings Per Share (EPS)

Net Profit after tax as per statement of Profit and Loss attributable to Equity shareholders.

478.74

458.77

Weighted Average number of equity shares used as denominator for calculating Adjusted EPS

15.60

15.60

Basic and Diluted Earnings per share (Rs.)

30.69

29.41

Face Value per equity share (Rs.)

10.00

10.00

27. Contingent Liability

For Income Tax

12.65

12.65

Total**12.65****12.65**

DHRUVI PHARMA PVT. LTD.**Notes forming part of Financial Statement****28 : Related Party Disclosure**

The Name of related parties with relationship and transactions with the are disclosed as under:

(A) Relationship

(I) Holding Company:
Keimed Pvt Ltd

(II) Subsidiary Companies:
ATC Pharma Pvt. Ltd.
Yashvi Pharma Pvt. Ltd.
Anila Medical Pvt. Ltd. (W.e.f.23.06.2021)

(III) Associate Entities:
Neelkanth Drugs Pvt. Ltd.
Meher Distribution Pvt. Ltd.
Papelu Pharma Pvt. Ltd.
Medihauxe Pharma Pvt. Ltd.
Sanjeevani Pharma Distributors Private Limited

(IV) Key Management Personnels:
Shri Rupeshbhai Shah - Managing Director
Smt Deeptiben Shah - Director

(V) Enterprise where Key managerial personal or principal shareholders have control or significant influence(" Significant interest entities")
Apollo Hospital Enterprise Limited
Apollo Hospitals International Limited
Apollo Healthco Limited
Apollo Pharmacies Limited

(B) The following transactions were carried out with related parties referred above in the ordinary course of business (excluding reimbursement).

		(Amount in Rs.Lakhs)	
		2021-22	2020-21
(I) Holding Company:-			
1	Logistic Charges paid (Excluding GST) Keimed Private Limited		
2	Purchase of goods (Excluding GST) Keimed Private Limited	193.05	175.23
3	Corporate Guarantee balance at the end of year Keimed Private Limited	156.91	58.62
4	Dividend paid Keimed Private Limited	3,600.00	3,000.00
5	Sale of Goods (Excluding GST) Keimed Private Limited	109.20	NIL
6	Loan Accepted Keimed Private Limited	0.39	NIL
7	Interest Expense Keimed Private Limited	400.00	NIL
8	Net closing balance Keimed Private Limited	28.78	NIL
		400.00	NIL

		(Amount in Rs. Lakhs)	
		2021-22	2020-21
(II) Subsidiary Companies:			
1	Sale of goods		
	ATC Pharma Pvt. Ltd.	73.77	38.53
	Anila Medical Pvt. Ltd.	2.10	NIL
2	Purchase of goods		
	ATC Pharma Pvt. Ltd.	137.30	382.62
	Anila Medical Pvt. Ltd.	8.14	NIL
3	Interest income		
	ATC Pharma Pvt. Ltd.	11.91	3.14
	Anila Medical Pvt. Ltd.	12.08	NIL
4	Interest Expense		
	ATC Pharma Pvt. Ltd.	NIL	0.08
5	ICD/Loan accepted		
	ATC Pharma Pvt. Ltd.	NIL	50.00
6	ICD/Loan repaid		
	ATC Pharma Pvt. Ltd.	NIL	50.00
7	ICD/Loan given		
	ATC Pharma Pvt. Ltd.	410.00	705.00
	Anila Medical Pvt. Ltd.	280.00	NIL
8	Recovery of ICD/Loan given		
	ATC Pharma Pvt. Ltd.	360.00	640.00
	Anila Medical Pvt. Ltd.	50.00	NIL
9	Net closing balance debit		
	ATC Pharma Pvt. Ltd.	190.00	143.65
	Anila Medical Pvt. Ltd.	230.00	NIL
(III) Associate Entities:-			
1	Sale of goods		
	Medihauxe Pharma Private Limited	2.21	NIL
	Meher Distribution Pvt. Ltd.	9.12	NIL
	Medihauxe International Private Lim	55.28	NIL
	Medihauxe Healthcare Private Limite	27.37	NIL
	Sanjeevani Pharma Distributors Priv	11.36	NIL
	Neelkanth Drugs Pvt. Ltd.	0.76	NIL
2	Purchase of goods		
	Neelkanth Drugs Pvt. Ltd.	297.18	199.52
3	Net closing balance - Debit	NIL	NIL
(IV) Key Management Personnels:			
(A)			
1	Remunerations		
	Shri Rupeshbhai Shah	48.00	48.00
2	ICD/Loan accepted		
	Shri Rupeshbhai Shah	120.00	20.00
3	ICD/Loan repaid		
	Shri Rupeshbhai Shah	50.00	NIL
4	Interest expense		
	Shri Rupeshbhai Shah	15.13	15.13
5	Personal Guarantee balance at the end of year		
	Shri Rupeshbhai Shah	360.00	300.00
6	Sale of goods		
	Shri Rupeshbhai Shah	1.87	0.10
7	Dividend paid		
	Shri Rupeshbhai Shah	23.40	NIL
8	Net closing balance-Credit	240.25	170.25

		(Rs. In Lakhs)	
		2021-22	2020-21
(B)			
1	Remunerations		
	Smt Deeptiben Shah	24.00	24.00
2	ICD/Loan accepted		
	Smt Deeptiben Shah	118.00	20.00
3	ICD/Loan repaid		
	Smt Deeptiben Shah	50.00	NIL
4	Interest expense		
	Smt Deeptiben Shah	16.87	15.13
5	Personal Guarantee balance at the end of year		
	Smt Deeptiben Shah	360.00	300.00
6	Dividend Paid		
	Smt Deeptiben Shah	23.40	NIL
7	Net closing balance - Credit	238.25	170.25
(V) Significant Interest Entities			
1	Sale of goods		
	Apollo Hospital Enterprise Limited	15,160.31	13,368.41
	Apollo Pharmacies Limited	NIL	14.36
	Apollo Healthco Limited	1,728.91	NIL
2	Net closing balance - Debit	1,199.92	1,492.40

DHRUVI PHARMA PRIVATE LIMITED

NOTES TO ACCOUNTS FOR THE YEAR ENDED 31ST MARCH 2022

Significant Accounting Policies, Standards and Notes on Accounts

29. Notes on Accounts

- There are no claims against the company acknowledged as debts.
- Confirmation of balances remains to be received in respect of debtors, creditors and advances and the balances as appearing in the books of account at the end of the year.
- Sundry debtors are considered good for which the company holds no security other than the debtor's personal security.
- Particulars of Managerial Remuneration (Amounts Rs. In lakhs)**

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Director Remuneration	72.00	72.00

- Particulars of Payment made to Auditors (Amounts Rs. In lakhs)**

Particulars	For the year ended 31 March 2022	For the year ended 31 March 2021
Statutory Audit Fees	7.50	7.00

- Foreign Currency Inflow & Outflow (Amounts Rs. In lakhs)**

Particulars	For the Year Ended 31 Mar 2022		For the Year Ended 31 Mar 2021	
	Amount in Foreign Currency	Amount in Indian Rupees	Amount in Foreign Currency	Amount in Indian Rupees
INFLOW OF FOREIGN EXCHANGE				
	NIL	NIL	NIL	NIL

DHRUVI PHARMA PRIVATE LIMITED

NOTES TO ACCOUNTS FOR THE YEAR ENDED 31st MARCH 2022

Significant Accounting Policies, Standards and Notes on Accounts

Particulars	For the Year Ended 31 Mar 2022		For the Year Ended 31 Mar 2021	
	Amount in Foreign Currency	Amount in Indian Rupees	Amount in Foreign Currency	Amount in Indian Rupees
EXPENDITURE OF FOREIGN EXCHANGE				
Import of Goods & Services	NIL	NIL	NIL	NIL
Dividend Payments	NIL	NIL	NIL	NIL
Travelling Expenses - Directors	NIL	NIL	NIL	NIL
Travelling Expenses - Directors	NIL	NIL	NIL	NIL
TOTAL	NIL	NIL	NIL	NIL

d) Employee benefits

As per Accounting Standard 15 "Employee Benefits", the disclosure as defined in the standard are given below:

The Company has recognized and debited a sum of Rs. 57.55 lakhs towards post-employment defined contribution plans comprising of provident and employee's state insurance to the Profit and Loss Account and Rs.5,30,621/- towards Gratuity. The Gratuity Liability of Rs. 39.83 Lakhs is provided based on the valuation of the actuary as per Accounting Standard 15.

I. PRINCIPAL ACTUARIAL ASSUMPTIONS [Expressed as weighted averages]	31 03 2022	31 03 2021
Discount Rate	6.87%	6.84%
Salary escalation rate	6%	6%
Expected rate of return on Plan Assets	NIL	NIL

(Rs. In Lakhs)

II. CHANGES IN THE PRESENT VALUE OF THE OBLIGATION (PVO) - RECONCILIATION OF OPENING AND CLOSING BALANCES:	31 03 2022	31 03 2021
PVO as at the beginning of the period	36.88	32.29
Interest Cost	2.53	2.21
Current service cost	5.16	4.93
Past service cost - (non vested benefits)	NIL	NIL
Past service cost - (vested benefits)	NIL	NIL
Benefits paid & Charges deducted	(2.87)	(0.72)
Actuarial loss/(gain) on obligation (balancing figure)	(1.86)	(1.84)
PVO as at the end of the period	39.83	36.88

DHRUVI PHARMA PRIVATE LIMITED

NOTES TO ACCOUNTS FOR THE YEAR ENDED 31st MARCH 2022

Significant Accounting Policies, Standards and Notes on Accounts

III. CHANGES IN THE FAIR VALUE OF PLAN ASSETS - RECONCILIATION OF OPENING AND CLOSING BALANCES:	31 03 2022	31 03 2021
Fair value of plan assets as at the beginning of the period	NIL	NIL
Expected return on plan assets	NIL	NIL
Contributions	NIL	NIL
Benefits paid & Charges deducted	NIL	NIL
Actuarial gain/(loss) on plan assets [balancing figure]	NIL	NIL
Fair value of plan assets as at the end of the period	NIL	NIL

IV. FAIR VALUE OF ON PLAN ASSETS	31 03 2022	31 03 2021
Fair value of plan assets at the beginning of the period	NIL	NIL
Acquisition adjustment	NIL	NIL
Actual return on plan assets	NIL	NIL
Employer contributions	NIL	NIL
Benefits paid	NIL	NIL
Fair value of plan assets at the end of the period	NIL	NIL
Funded status	NIL	NIL
Excess of actual over estimated return on plan assets	NIL	NIL

V. ACTUARIAL GAIN / LOSS RECOGNIZED	31 03 2022	31 03 2021
Actuarial (gain) / loss for the period - Obligation	(1.86)	(1.84)
Actuarial (gain) / loss for the period- Plan Assets	NIL	NIL
Total (gain) / loss for the period	(1.86)	(1.84)
Actuarial (gain) / loss recognized in the period	(1.86)	(1.84)
Unrecognized actuarial (gain) / loss at the end of the year	NIL	NIL

VI. AMOUNTS RECOGNISED IN THE BALANCE SHEET AND RELATED ANALYSES	31 03 2022	31 03 2021
Present value of the obligation	39.83	36.88
Fair value of plan assets	NIL	NIL
Difference	39.83	36.88
Unrecognised transitional liability	NIL	NIL
Unrecognised past service cost - non vested benefits	NIL	NIL
Liability recognized in the balance sheet	39.83	36.88

DHRUVI PHARMA PRIVATE LIMITED

NOTES TO ACCOUNTS FOR THE YEAR ENDED 31st MARCH 2022

Significant Accounting Policies, Standards and Notes on Accounts

VII. EXPENSES RECOGNISED IN THE STATEMENT OF PROFIT AND LOSS:	31 03 2022	31 03 2021
Current service cost	5.16	4.93
Interest Cost	2.53	2.21
Expected return on plan assets	(1.86)	(1.84)
Net actuarial (gain)/loss recognised in the year	NIL	NIL
Transitional Liability recognised in the year	NIL	NIL
Past service cost - non-vested benefits	NIL	NIL
Past service cost - vested benefits	NIL	NIL
Expenses recognized in the statement of profit and loss	5.83	5.31

VIII. RECONCILIATION STATEMENT OF EXPENSE IN THE STATEMENT OF PROFIT AND LOSS	31 03 2022	31 03 2021
Present value of obligation as at the end of period	39.83	36.88
Present value of obligation as at the beginning of period	36.88	32.29
Benefits paid	(2.87)	(0.72)
Actual return on plan assets	NIL	NIL
Acquisition adjustment	NIL	NIL
Expenses recognised in the statement of profit & losses	5.83	5.30

Assumptions at the valuation date

Discount rate: The discount rate of 6.87 % is based on the gross redemption yield on medium to long-term risk-free investments.

Salary escalation rate: The estimates of future salary increase considered takes into account the inflation, seniority, promotion and other relevant factors such as supply and demand factors in the employment market. The future salary increase has been taken as 6 % and the Retirement age has been taken as 60 years.

- e) The Company has sent out letters seeking confirmations from its suppliers whether they fall under the category of micro, small and medium enterprises as mentioned under the Micro, Small and Medium Enterprises Development Act, 2006. Based on the information available with the Company, the Company believes that it does not have any outstanding dues to micro, small and medium enterprises. Further, the Company has not paid any interest to the micro, small and medium enterprises.
- f) The Company was sanctioned Credit Facilities / Term Loans by Banks / Financial Institutions and the proceeds of the Facilities sanctioned by the Banks / Financial Institutions were utilised for the purpose for which the facilities were sanctioned. No loans / advances were

DHRUVI PHARMA PRIVATE LIMITED

NOTES TO ACCOUNTS FOR THE YEAR ENDED 31ST MARCH 2022

Significant Accounting Policies, Standards and Notes on Accounts

given out of the proceeds of the Facilities were given by the Company and no revenue expenditure was met out of the proceeds of the Facilities.

- e) The Company had not revalued any of the Assets during the financial year 2021-22.
- f) The Company had not advanced any Loans to the Directors / Promoters / Key Managerial Persons during the year 2021-22.
- g) The Company does not have any Capital Work in Progress either Tangible or Intangible as on 31 March 2022.
- h) The Company does not have any Property held by others on behalf of the Company as on 31st March 2022.
- i) The Company does not have any transactions with the Struck Off Companies as on 31st March 2022.
- j) As on 31st March 2022, the Company does not have any pending issues with regards to Creation / Modification / Satisfaction of Charges for the Credit Facilities sanctioned by the Banks / Financial Institutions.
- k) The Company has Three Subsidiary Company. However, none of the Subsidiary Company has Subsidiary Companies. Hence, the provisions of the Companies Act 2013 with regards to the restriction of number of layer of companies is not violated by the Company.
- l) The Company did not avail any Schemes / Arrangements approved by any Government Authority.
- m) During the Financial Year 2021-22, the Company had availed Rs. 33 crores towards Working Capital Facilities from HDFC Bank.
- n) During the year 2021-22, there is no undisclosed income.
- o) The Company is required to spend Rs. 10.83 Lakhs during the year 2021-22 and Rs. 7.85 Lakhs for P.Y. 2020-21 towards Corporate Social Responsibility.

DHRUVI PHARMA PRIVATE LIMITED

NOTES TO ACCOUNTS FOR THE YEAR ENDED 31st MARCH 2022

Significant Accounting Policies, Standards and Notes on Accounts

(Rs. In Lakhs)

Amount Required to be Spent Rs.	Amount Actually Spent Rs.	Short-fall, if any Rs.	Previous years' Short fall Rs.	Total Short fall Rs.	Reasons for short fall	Nature of CSR Activity
10.83	10.85	NIL	NIL	NIL	NA	Contribution to various foundation and trusts

The Company does not have any relationship with the Trust / Entity, through which the CSR Expenditure is met.

The Company does not have any contractual obligation with the Trust / Entity through which the CSR Expenditure is met.

- r) As on 31st March 2022, the Company is not declared as a "Willful Defaulter" by any Bank / Financial Institution / Private Lendor.
- s) The Company does not deal with any Crypto / Virtual Currency.
- t) Ratio Analysis

On March 24, 2021, the Ministry of Corporate Affairs ("MCA") through a notification, amended Schedule III of the Companies Act, 2013. The amendments revise Division I, II and III of Schedule III and are applicable from April 1, 2021. However, amendments relating disclosure of ratio are disclosed here:

S. No.	Description of Ratio	Rs. In Lakhs		FY 2021-22 Ratio	FY 2020-21 Ratio	Variance
		Numerator	Denominator			
1	Current Ratio	6,678.62	5,003.04	1.33	1.30	2.99%
2	Debt Equity Ratio	4,249.72	2,276.42	1.87	1.52	22.84%
3	Debt Service Coverage Ratio	1,063.08	293.52	3.62	3.75	-3.43%
4	Return on Equity Ratio	478.74	1,503.05	0.32	0.41	-22.78%
5	Inventory to Turnover Ratio	38,579.99	2,587.61	14.91	12.83	16.20%
6	Trade Receivables to Turnover Ratio	38,579.99	3,619.68	10.66	9.22	15.57%

DHRUVI PHARMA PRIVATE LIMITED

NOTES TO ACCOUNTS FOR THE YEAR ENDED 31st MARCH 2022

Significant Accounting Policies, Standards and Notes on Accounts

- x) As per sub rule 6 of the Companies Accounts Rules, 2014 read with section 129 of the Companies Act, 2013, the company has availed exemption for not preparing consolidated financial statement.

- y) Disclosure as required under section 186(4) of the companies act, 2013

(Rs. In Lakhs)

Particulars	31.03.2022	Rate of interest	31.03.2021
Loan given for long term business requirement			
ATC Pharma Pvt Ltd.	190.00	8.5%	140.00
Anila Medical Pvt. Ltd.	230.00	8.5%	NIL
Yashvi Pharma Pvt. Ltd.	1.00	NIL	1.00
Investment in equity Shares of:			
ATC Pharma Pvt Ltd.	765.00		765.00
Anila Medical Pvt. Ltd.	499.80		NIL
Yashvi Pharma Pvt. Ltd.	1.00		1.00

- z) Segment Reporting

Disclosure requirements under Accounting Standards 17 on 'Segment Reporting'

The Company has only one Business Segments viz., Trading in Life Saving Medicines. Hence, disclosure of details under AS 17 does not apply.

DHRUVI PHARMA PRIVATE LIMITED

NOTES TO ACCOUNTS FOR THE YEAR ENDED 31st MARCH 2022

Significant Accounting Policies, Standards and Notes on Accounts

aa) Dividend Paid and Proposed

Particulars	(Rs. In Lakhs)	
	For the Year Ended 31 Mar 2022	For the Year Ended 31 Mar 2021
A) Dividend Declared and Paid During The Year	156.00	NIL
Final Dividend For The Year 2020-21	78.00	NIL
Final Dividend Paid	78.00	NIL
Interim Dividend For The Year 2021-22	78.00	NIL
Interim Dividend Paid	78.00	NIL
B) Dividend Proposed During The Year	78.00	78.00

Signatures for Notes 1 to 29

As per our report of even date attached

For Hemanshu Shah & Co.,
Chartered Accountants
Firm Registration No.
122439W




H. C. Shah
Partner



Place: Ahmedabad

Date : 2nd June, 2022

For and on behalf of Board of Directors of
Dhruvi Pharma Private Limited



Rupesh Hemendra Shah
Managing Director
DIN : 00029134



Arvind Kumar Venkat
Director
DIN : 02304618

